Lumos Diagnostics (ASX: LDX) has achieved complete US Medicare reimbursement recognition for its FebriDx point-of-care diagnostic test, securing coverage from all seven Medicare Administrative Contractors (MACs).
The final approval came from National Government Services, which manages Medicare payments across the Midwest, New England, and New York regions.
Lumos said the milestone places FebriDx on the US Clinical Lab Fee Schedule at US$41.38 per test, positioning the company for broader adoption across the national healthcare system.
Complete Nationwide Coverage
The inclusion of National Government Services follows earlier approvals from CGS, Novitas, Palmetto, First Coast Service Options, Noridian Healthcare Solutions and WPS Health Solutions.
Collectively, the seven MACs represent the entirety of the Medicare payment system, meaning FebriDx is now recognised for reimbursement in every US region.
Medicare accounts for roughly 20%–24% of the national payor mix, making full coverage a critical step toward widespread clinical use.
Lumos will now shift its focus to assisting each MAC develop the formal written reimbursement policies typically used by Medicare Advantage and Medicaid plans as reference points when establishing their own payment frameworks, which will provide clear rules for claims processing and reduce administrative uncertainty for healthcare providers.
Lumos’ partner PRO-spectus will support both MACs and other private payors as they integrate FebriDx coverage into internal systems.
Broader US Market Adoption
Chief executive officer Doug Ward said securing reimbursement from all seven MACs is “a landmark achievement for Lumos” that will help position FebriDx for broad adoption across the US healthcare system.
He said full Medicare recognition unlocks nationwide access and paves the way for wider uptake across Medicare Advantage, Medicaid and private insurers.
The reimbursement milestone enhances predictability for clinicians and laboratories using FebriDx, which differentiates viral from bacterial causes of fever and inflammation at the point of care.
Lumos intends to continue working with payors to streamline coverage integration and support expanded clinical deployment.
The company noted that full Medicare recognition strengthens its US commercial strategy as it seeks to build adoption across acute care, primary care, and community health settings.
